Clinical trials: Antipsychotic
Bipolar I Disorder
Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients
The purpose of this study is to determine whether Bipolar I Disorder refractory treatment with Quetiapine monotherapy could be better potentiated with Lithium or Aripiprazole.
- Trial name
- ARIQUELI (NCT01710163)
- Testing
- Lithium, Aripiprazole
- Where
- 2 sites in Brazil
- Volunteers
- 50 people
- Sponsor
- University of Sao Paulo
Schizophrenia
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent…
- Trial name
- NCT00616798
- Testing
- RO4917838, Standard antipsychotic therapy
- Where
- 73 sites in United States, Austria and 8 more
- Volunteers
- 323 people
- Sponsor
- Hoffmann-La Roche
Hyperactive Delirium
Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium
In population of intensive care unit (ICU), most studies compared atypical antipsychotics such as quetiapine with the traditional haloperidol in delirious patients of various forms and etiologies.
- Trial name
- NCT05690698
- Testing
- Quatiapine, Haloperidol
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Conditions
- Schizophrenia, Psychotic Disorders, Psychosis
- Trial name
- PAFIP3_nc3Y (NCT03883204)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Weight Gain
Effects of Modafinil on Olanzapine Weight Gain
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively.
- Trial name
- NCT00636896
- Testing
- Olanzapine plus modafinil
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neuropsychiatric Research Institute, Fargo, North Dakota
Schizophrenia
Schizophrenia Sensory Gating Deficit With Quetiapine
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to…
- Trial name
- NCT00536783
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New Mexico VA Healthcare System
Borderline Personality Disorder
Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
Objective: The objective of this study is to quantitatively examine the efficacy of Seroquel (active ingredient quetiapine fumarate) in subjects with Borderline Personality Disorder (BPD).
- Trial name
- NCT00122070
- Testing
- Quetiapine Fumarate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Medicine and Dentistry of New Jersey
Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
Olanzapine is a thieno-benzodiazepine derivate that is effective managing the symptoms of schizophrenia and reducing the psychopathological symptoms of psychosis.
- Trial name
- NCT05669742
- Testing
- Empagliflozin, olanzapine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Tanta University
Schizophrenia, Schizoaffective Disorder
Salsalate as an Adjunctive Treatment for Patients With Schizophrenia
This is a 12-week, open-label trial of salsalate 3 g/day as an adjunctive treatment in 15 schizophrenia subjects to examine salsalate's effect on psychopathology, cognitive functioning, and metabolic parameters.
- Trial name
- NCT01578486
- Testing
- salsalate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia, Diabetes
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
Patients suffering from schizophrenia have a high risk to become obese and develop diabetes. Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine or olanzapine.
- Conditions
- Schizophrenia, Diabetes, Insulin Resistance
- Trial name
- NCT01160991
- Testing
- Glucose clamp technique, Amisulpride, Olanzapine
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia
Subjective Well Being of Schizophrenic Patients in Greece
Non-interventional study aiming to provide data on the subjective effects of antipsychotic medication assessing subjective well-being and global functioning of patients with Schizophrenia under antipsychotic medication.
- Trial name
- AURA (NCT00857064)
- Where
- 24 sites in Greece
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Functional Dyspepsia
Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia
The goal of this clinical trial is to assess and compare the effect of amitriptyline and trifluoperazine in improving dyspeptic symptoms in patients with functional dyspepsia.
- Trial name
- NCT07008235
- Testing
- Tablet Amitriptyline 10 milligrams, Tablet Trifluoperazine 1 milligrams twice daily, Standard First-Line Therapy
- Where
- Bangladesh
- Volunteers
- 120 people
- Sponsor
- Md. Moktadirul Hoque Shuvo
Schizophrenia
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
- Trial name
- CONVOKE (NCT05838625)
- Testing
- CT-155, Digital Control
- Where
- 54 sites in United States
- Volunteers
- 464 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on AOM treatment during an schizophrenia-related hospitalisation at least 6 months before data…
- Trial name
- PROSIGO (NCT03130478)
- Where
- 15 sites in Spain
- Volunteers
- 119 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Schizophrenia, Hepatic Impairment
A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
The purpose of this study is 1) to investigate the single-dose pharmacokinetics of immediate release (IR) paliperidone, after oral administration, in patients having moderate hepatic impairment compared to patients having normal…
- Trial name
- NCT00791284
- Testing
- Intermediate release (IR) Paliperidone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia
The purpose of this study is to compare the effectiveness and safety over 1 year of treatment of intramuscular injections of paliperidone palmitate and long-acting risperidone in patients with schizophrenia.
- Trial name
- NCT00210717
- Testing
- paliperidone palmitate
- Volunteers
- 748 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
This program aims to help Veterans who take antipsychotic medications lose weight. We use a program based on the American Diabetes Association's "Diabetes Prevention Program," and we have modified it to fit the lifestyles of…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO2 (NCT01052714)
- Testing
- Lifestyle Balance
- Where
- 3 sites in United States
- Volunteers
- 121 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Treatment for First-Episode Schizophrenia
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
- Trial name
- NCT00000374
- Testing
- Olanzapine, Risperidone
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Northwell Health
Bipolar Disorder
Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder
The clinical use of clozapine has been an unequivocal advance in the treatment of schizophrenia, a chronic and severe mental illness.
- Trial name
- NCT02562287
- Testing
- Clozapine, Risperidone, Olanzapine
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Alzheimer's Disease
CATIE-Alzheimer's Disease Trial
The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or…
- Trial name
- NCT00015548
- Testing
- Olanzapine, Quetiapine, Risperidone
- Where
- 34 sites in United States
- Volunteers
- 450 people
- Sponsor
- National Institute of Mental Health (NIMH)